Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

NCT00053157 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions

BIOLOGICAL: sargramostim

Sponsor

Roswell Park Cancer Institute